Search

Two novel complexes were synthesized by the reaction of benzothiazol‐pyrimidin‐2‐ylidene ligand (BTP) with Pd (II) and Fe (III) ions. A variety of various spectral and analytical methods (infrared, 1H/NMR, 13C/NMR, electronic spectra, CHN analyses, mass spectra, thermogravimetric analysis, and magnetic susceptibility) were used to characterize the investigated BTP ligand and its complexes. Correlation of experimental results with density functional theory calculation proves that the geometry of BTP‐Fe complex is octahedral, whereas BTP‐Pd complex is square planner. The catalytic effectiveness of BTP complexes were tested for three‐component condensation process under moderate and environmentally friendly reaction conditions. Moreover, the effects of different Lewis acid, basic, and ionic liquid catalysts, as well as solvent and catalyst dose on the catalytic reaction were investigated. Both catalysts demonstrated strong catalytic capability in the carefully regulated ideal reaction circumstances. Heterogeneous catalyst BTP‐Pd exhibited superior catalytic performance compared to homogeneous catalyst BTP‐Fe. All products were obtained in high TOF (turnover frequency) numbers in the presence of these catalysts, which indicate the high efficiency of these catalysts in the synthesis of dihydro‐7H‐5‐thia‐hexaaza‐s‐indacen‐6‐one derivatives. Moreover, the two catalysts' recycling and reusability in reactions were also investigated. Heterogeneous BTP‐Pd catalyst could be reused up to seven times with high efficiency, but the homogeneous catalyst (BTP‐Fe) could only be recycled up to four times. Furthermore, the mechanism of catalytic reaction was suggested and supported by DFT calculation. The simplicity, safety, stability, use of commercially available catalysts, quick reaction times, and excellent yields make it promising for future industrial use. [ABSTRACT FROM AUTHOR]

In this study, novel selective antitumor compounds were synthesized based on their fundamental pharmacophoric prerequisites associated with EGFR inhibitors. A molecular hybridization approach was employed to design and prepare a range of 4H-chromene-3-carboxylates 7a–g, 8, and 11a–e derivatives, each incorporating a sulfonamide moiety. The structures of these hybrid molecules were verified using comprehensive analytical and spectroscopic techniques. During the assessment of the newly synthesized compounds for their anticancer properties against three tumor cell lines (HepG-2, MCF-7, and HCT-116), compounds 7f and 7g displayed remarkable antitumor activity against all tested cell lines, outperforming the reference drug Cisplatin in terms of efficacy. Consequently, these promising candidates were selected for further investigation of their anti-EGFR, hCAII, and MMP-2 potential, which exhibited remarkable effectiveness against EGFR and MMP2 when compared to Sorafenib. Additionally, docking investigations regarding the EGFR binding site were implemented for the targeted derivatives in order to attain better comprehension with respect to the pattern in which binding mechanics occur between the investigated molecules and the active site, which illustrated a higher binding efficacy in comparison with Sorafenib. [ABSTRACT FROM AUTHOR]

In this work, we used microwave irradiation conditions to synthesize β-enaminonitrile (4), which was affirmed using single crystal X-ray diffraction and the different spectral data. Two tumor cell lines, MCF-7 and MCF-7/ADR, as well as two normal cell lines, HFL-1 and WI-38, were used to assess the anticancer activity of compound 4. The studied molecule exhibited potent efficacy against the MCF-7 and MCF-7/ADR cell lines compared with the reference drugs. Furthermore, target compound 4 had feeble activity against HFL-1 and WI-38. The chemical reactivity was discussed using DFT and QTAIM analysis to study the intrinsic electronic properties of compound 4. A molecular docking study was also conducted to examine their binding affinity to the EGFR. Compound 4 revealed a stable binding mode at the enzyme active pocket more than the reference inhibitor. The docking analysis was performed for molecule (4). [ABSTRACT FROM AUTHOR]

We have studied the dielectric properties and electrical conductivity for pure bentonite (Ben) and Ben loaded with 1.0%, 3.0% and 10.0% Ni composition within the temperature range 25°C–110°C and over the frequency range (100 Hz–0.3 MHz). The dielectric permittivity of pure Ben and Ni/Ben composite decreased with increasing frequency and temperature. We observed two relaxation processes in the characteristics of the electric modulus as a function of frequency and temperature. For both pure Ben and Ni/Ben, the activation energy decreased with increasing frequency and further decreased by adding 1.0, 3.0 and 10.0 wt.% Ni. Thus, the conduction mechanism in Ni/Ben has been associated with small polaron tunnelling. [ABSTRACT FROM AUTHOR]

There is concern for important adverse effects with use of second-generation antipsychotics in Parkinson's disease psychosis (PDP) and dementia-related psychosis. Pimavanserin is the only antipsychotic drug authorized for PDP and represents an inverse agonist of 5-HT 2A receptors (5-HT2AR) lacking affinity for dopamine receptors. Therefore, the development of serotonin 5-HT2AR inverse agonists without dopaminergic activity represents a challenge for different neuropsychiatric disorders. Using ligand-based drug design, we discovered a novel structure of pimavanserin analogues ( 2 , 3 , and 4 ). In vitro competition receptor binding and functional G protein coupling assays demonstrated that compounds 2 , 3 , and 4 showed higher potency than pimavanserin as 5-HT2AR inverse agonists in the human brain cortex and recombinant cells. To assess the effect of molecular substituents for selectivity and inverse agonism at 5-HT2ARs, molecular docking and in silico predicted physicochemical parameters were performed. Docking studies were in agreement with in vitro screenings and the results resembled pimavanserin.

Background: Molecules bearing an active methylene bridge are one of the most fruitful and remarkable precursors that have been incorporated into the synthetic strategy of an assortment of bioactive compounds., Objective: The reactive methylene derivatives have been endowed with multiple reactions, which target biological and medicinal applications and result from their structural diversity and discrete reactivity., Methods: The present report endeavors to synthesize, characterize, and in-vitro evaluate several novel propanoic acids, coumarin, and pyrazole derivatives as antimicrobial and antiproliferative agents. The in-silico molecular docking, physicochemical, pharmacokinetic/ADMET, bioactivity, and drug-likeness predictions were conducted for all the synthesized compounds., Results: The highest docking score is -9.9 and -8.3 kcal/mol, respectively, for compound 9 (azocoumarin) and 13 (acrylic acid derivative) with the target proteins E. coli topoisomerase II, DNA gyrase subunit B and PI3K p110α domain, respectively. Moreover, this study predicts the synthesized molecules that may inhibit the novel COVID-19, obtained through virtual screenings only, where compounds 9, 13, 14, 17, and 19 came to the limelight with good docking scores i.e., more than -8 Kcal/mol. Safety profiling of the most potent compound 9 was utilized against normal cell lines and the hemolytic effect on RBCs., Conclusion: The in-silico ADMET studies of the synthesized compounds revealed moderate to good -likeness, high gastro intestinal (GI) absorption, and inhibiting the Cytochrome CYP2C19 and CYP2C9 and all the derivatives possess non-cancerous nature. The in-vitro screening demonstrated that several of the novel molecules are promising drug candidates. The density functional theory (DFT) theoretical calculations were performed to calculate the energy levels of the FMOs and their energy gaps, dipolemoment, andmolecular electrostatic potential. Such parameters, along with the physicochemical parameters, could be a good tool to confirm biological activity., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)